12:00 AM
 | 
Feb 01, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Luminate: Completed Phase IIb enrollment

Allegro completed enrollment of 120 patients in the double-blind, placebo-controlled, U.S. Phase IIb DEL MAR trial comparing 1, 2 and 3 mg intravitreal Luminate vs. Avastin bevacizumab. Patients will receive Luminate or Avastin at day 0 and weeks 4 and...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >